Comparative Pharmacology
Head-to-head clinical analysis: LO OVRAL versus SOJOURN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO OVRAL versus SOJOURN.
LO/OVRAL vs SOJOURN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin oral contraceptive; suppresses gonadotropin release, primarily FSH and LH, inhibiting ovulation; increases viscosity of cervical mucus, impeding sperm penetration; alters endometrial receptivity.
Selective norepinephrine reuptake inhibitor (NRI) that increases norepinephrine levels in the synaptic cleft, enhancing adrenergic transmission primarily in the descending pain pathways of the spinal cord.
One tablet (30 mcg ethinyl estradiol, 0.3 mg norgestrel) orally once daily for 28-day cycle (21 active, 7 placebo).
400 mg orally once daily
None Documented
None Documented
Norgestrel (levonorgestrel): 11-45 hours (mean ~24 hours); ethinyl estradiol: 7-21 hours (mean ~14 hours). Half-life increases slightly with repeated dosing due to saturable metabolism.
Terminal half-life 12-15 hours; clinical context: supports twice-daily dosing in most patients.
Urine (50-60% as conjugated metabolites), feces (30-40% as metabolites), enterohepatic recirculation present.
Renal: 70% unchanged; biliary/fecal: 20% as metabolites; 10% in expired air.
Category C
Category C
Combination Oral Contraceptive
Combination Oral Contraceptive